Journal: Journal of Chronic Fatigue Syndrome
. Vol. 13(4) 2006 pp. 31-43. [Published online ahead of print. Article copies are available for a fee from The Haworth Document Delivery Service: 1-800-HAWORTH. E-mail address: email@example.com
; Website: http://www.HaworthPress.com
.] Authors and affiliation: Carl-Gerhard Gottfries, Ove Häger, Björn Regland, Olof Zachrisson. Institute of Clinical Neuroscience, University of Gothenburg Sweden. [E-mail firstname.lastname@example.org] DOI: 10.1300/J092v13n04_04 31
One hundred and sixty patients with Fibromyalgia and Chronic Fatigue Syndrome, who were on a continuous treatment with a Staphylococcus vaccine, were followed during one year with repeated consultation visits. The patients had participated in controlled studies and been on continuous treatment with the vaccine for 22+/-10 months before inclusion in this follow-up study. They were treated with 1 mL of the vaccine subcutaneously every third to fourth week.
Adverse events were few. The adherence to the treatment was very good. Over a period of one year, 8% withdrew, and in only 5%, the withdrawal was due to insufficient clinical effect. Only in two cases where the patients were allergic to the preservative of the vaccine, the side effects caused the withdrawal of the treatment.
Ratings with scales (CPRS-15 and FibroFatigue) showed improvement from start of treatment and also further improvement during the follow-up year. In view of the natural history for these disorders the result is of interest.
Keywords: Fibromyalgia, chronic fatigue syndrome, Staphylococcus vaccine, long-term treatment